Diabetic Ketoacidosis Treatment Guidelines

Initial Assessment and Management

The American Diabetes Association recommends performing laboratory evaluation including plasma glucose, blood urea nitrogen/creatinine, serum ketones, electrolytes, osmolality, urinalysis, urine ketones, arterial blood gases, complete blood count, and electrocardiogram for patients with diabetic ketoacidosis (DKA) 1
Obtain bacterial cultures of urine, blood, and throat if infection is suspected and administer appropriate antibiotics for patients with DKA 1
Chest X-ray should be obtained if clinically indicated for patients with DKA 1

Fluid Resuscitation and Electrolyte Management

The American Diabetes Association recommends beginning with isotonic saline at a rate of 15-20 ml/kg body weight/hour for the first hour of treatment for DKA 1, 2
Total fluid replacement should be approximately 1.5 times the 24-hour maintenance requirements for patients with DKA 2
Include 20-30 mEq/L potassium in the infusion once renal function is assured for patients with DKA 1, 2
Monitor serum potassium closely as insulin therapy lowers serum potassium levels for patients with DKA 2

Insulin Therapy

The American Diabetes Association recommends continuous intravenous regular insulin infusion as the preferred treatment method for moderate to severe DKA 2, 3
Start with an IV bolus of regular insulin at 0.1 units/kg followed by continuous infusion at 0.1 units/kg/hour for patients with DKA 2, 3

Monitoring and Transition to Subcutaneous Insulin

Check blood glucose every 2-4 hours and measure serum electrolytes, glucose, blood urea nitrogen, creatinine, osmolality, and venous pH every 2-4 hours for patients with DKA 2, 3
When DKA resolves and the patient can eat, start a multiple-dose insulin schedule using a combination of short/rapid-acting and intermediate/long-acting insulin 2, 3
Administer basal insulin 2-4 hours before stopping the IV insulin infusion for patients with DKA 4

Manejo de Cetoacidosis Diabética con Insulina Subcutánea

Protocolo de Dosificación de Insulina Subcutánea

La dosis de ajuste de insulina debe reducirse a 0,05-0,1 U/kg/hora hasta la resolución completa de la cetoacidosis (pH ≥7,3, bicarbonato ≥18 mEq/L), según la guía de la Diabetes Care 5

Monitorización Durante el Tratamiento

La glucemia debe verificarse cada 2-4 horas mientras el paciente esté en ayuno, según la guía de la Diabetes Care 5

Insulin Regimen After DKA Resolution

Timing of Transition

Administer basal insulin (glargine or detemir) 2-4 hours BEFORE stopping the IV insulin infusion to prevent recurrence of ketoacidosis and rebound hyperglycemia, as recommended by the American Diabetes Association, with a strength of evidence based on clinical guidelines 6

Monitoring Requirements

Continue monitoring electrolytes, particularly potassium, as insulin drives potassium intracellularly, according to the American Association of Clinical Endocrinologists, with a strength of evidence based on clinical guidelines 6

Critical Pitfalls to Avoid

Do not stop IV insulin without prior basal insulin administration—this is the most common error leading to DKA recurrence, as warned by the American Diabetes Association, with a strength of evidence based on clinical guidelines 6

Discharge Planning

Structured discharge planning should begin at admission and include patient education on insulin administration, glucose monitoring, and sick day management, as recommended by the American Diabetes Association, with a strength of evidence based on clinical guidelines 6

Management of Insulin Infusion in DKA with Severe Hypokalemia

Critical Threshold for Insulin Initiation

The American Diabetes Association recommends delaying insulin infusion until serum potassium is ≥3.3 mEq/L to prevent life-threatening cardiac arrhythmias and death 7
Do not start insulin if potassium is <3.3 mEq/L, as this is the absolute cutoff established by the American Diabetes Association guidelines 7

Initial Management Algorithm

Begin isotonic saline at 15-20 ml/kg/hour for the first hour while holding insulin, as recommended by the American Diabetes Association 7
Once renal function is confirmed, add 20-40 mEq/L potassium to IV fluids, using a combination of 2/3 KCl or potassium-acetate and 1/3 KPO4 7
Obtain electrocardiogram to assess for cardiac effects of hypokalemia, as recommended by the American Diabetes Association 7
Continue aggressive potassium repletion until K+ ≥3.3 mEq/L, as recommended by the American Diabetes Association 7

Initiation of Insulin Therapy

Once K+ ≥3.3 mEq/L, start IV bolus of regular insulin at 0.1 units/kg, followed by continuous infusion at 0.1 units/kg/hour, as recommended by the American Diabetes Association 7
Target glucose decline of 50-75 mg/dl/hour, as recommended by the American Diabetes Association 7

Insulin Drip Protocol for Diabetic Ketoacidosis

Initial Insulin Dosing Protocol

The American Diabetes Association recommends giving an IV bolus of 0.1 units/kg regular insulin for adults with moderate-severe DKA, with a strength of evidence based on high-quality trials 8
The American Diabetes Association suggests starting a continuous infusion of 0.1 units/kg/hour regular insulin for adults with moderate-severe DKA, with a moderate strength of evidence based on clinical experience 9, 8
The target glucose decline is 50-75 mg/dL per hour, according to the American Diabetes Association, with a moderate strength of evidence based on clinical experience 8

Adjusting the Insulin Infusion

The American Diabetes Association recommends verifying adequate hydration status if glucose does not fall by 50 mg/dL in the first hour, with a low strength of evidence based on expert opinion 8
The American Diabetes Association suggests doubling the insulin infusion rate every hour until achieving a steady decline of 50-75 mg/dL/hour, with a moderate strength of evidence based on clinical experience 8

Concurrent Fluid and Electrolyte Management

The American Diabetes Association recommends using 2/3 KCl or potassium-acetate and 1/3 KPO4 for potassium replacement, with a moderate strength of evidence based on clinical experience 9, 8

Monitoring Requirements

The American Diabetes Association suggests checking venous pH every 2-4 hours, with a moderate strength of evidence based on clinical experience 9, 8
The American Diabetes Association recommends direct measurement of β-hydroxybutyrate in blood for ketone monitoring, with a high strength of evidence based on high-quality trials 9

DKA Resolution Criteria

The American Diabetes Association states that all of the following must be met for DKA resolution: glucose <200 mg/dL, serum bicarbonate ≥18 mEq/L, venous pH >7.3, and anion gap ≤12 mEq/L, with a moderate strength of evidence based on clinical experience 9

Transition to Subcutaneous Insulin

The American Diabetes Association recommends continuing IV insulin for 1-2 hours after subcutaneous insulin is given, with a moderate strength of evidence based on clinical experience 9

Alternative Approach for Mild-Moderate Uncomplicated DKA

The American Diabetes Association suggests that subcutaneous rapid-acting insulin analogs combined with aggressive fluid management can be as effective and more cost-effective than IV insulin for hemodynamically stable, alert patients with mild-moderate DKA, with a moderate strength of evidence based on clinical experience 10, 11

Initiating Subcutaneous Insulin in Diabetic Ketoacidosis

Transition Criteria

The American Diabetes Association recommends initiating subcutaneous insulin when diabetic ketoacidosis (DKA) has completely resolved (pH ≥7.3, bicarbonate ≥18 mEq/L, glucose <200 mg/dL, anion gap ≤12 mEq/L) and the patient can tolerate oral intake, administering it 2-4 hours before discontinuing intravenous insulin infusion to prevent DKA recurrence 12
The American Diabetes Association suggests that the transition from intravenous to subcutaneous insulin requires all of the following criteria to be met simultaneously: pH venous >7.3, bicarbonate serum ≥18 mEq/L, glucose <200 mg/dL, anion gap ≤12 mEq/L, and patient's ability to tolerate oral intake, with the patient being hemodynamically stable 12

Transition Protocol

The American Diabetes Association recommends administering long-acting basal insulin (glargine or detemir) subcutaneously 2-4 hours before discontinuing intravenous insulin infusion to allow for absorption and prevent DKA recurrence 12
The American Diabetes Association suggests initiating a multiple-dose regimen with a combination of short-acting/rapid insulin and intermediate-acting/long-acting insulin once the resolution criteria are met, and continuing intravenous infusion for 1-2 hours after administering subcutaneous insulin 12
The American Diabetes Association recommends monitoring glucose levels every 2-4 hours during the transition period 12

Alternative Approach for Mild to Moderate Uncomplicated DKA

For hemodynamically stable patients with mild to moderate DKA, subcutaneous insulin with rapid-acting analogs combined with aggressive fluid management may be as effective as intravenous insulin and more cost-effective, according to the American Diabetes Association 12
This approach requires the patient to be hemodynamically stable and alert, have mild to moderate DKA, receive adequate fluid replacement, and have frequent monitoring of capillary glucose levels 12

Monitoring During Transition

The American Diabetes Association recommends monitoring glucose levels every 2-4 hours during the transition period 12

Common Pitfalls to Avoid

The American Diabetes Association advises against discontinuing intravenous insulin without prior administration of subcutaneous basal insulin, as this is a common error that leads to DKA recurrence 12
The American Diabetes Association recommends against initiating subcutaneous insulin before complete resolution of metabolic acidosis 12
The American Diabetes Association suggests avoiding premature transition when the patient is still unable to tolerate oral intake 12

Insulin Infusion Discontinuation Criteria and Overlap Protocol in DKA

Basal Insulin Overlap Timing

Administer a long‑acting basal insulin (e.g., glargine or detemir) subcutaneously 2–4 hours before stopping the intravenous insulin infusion to ensure continuous insulin coverage and prevent rebound hyperglycemia or recurrent DKA. This recommendation is endorsed by the American Diabetes Association guidelines. 13
Maintaining the intravenous insulin infusion for 1–2 hours after the basal insulin injection allows adequate absorption of the subcutaneous dose and further reduces the risk of a coverage gap that can precipitate ketoacidosis. (Guideline‑based practice) 13

Monitoring Parameters Prior to Discontinuation

Prior to stopping the insulin infusion, check the following metabolic parameters every 2–4 hours until they remain stable:

Guideline Recommendations for Fluid Management, Electrolyte Replacement, Monitoring, and Insulin Transition in Adult Diabetic Ketoacidosis

Fluid Resuscitation

Potassium Replacement

Laboratory Monitoring

Transition to Subcutaneous Insulin

Subcutaneous Insulin Dose Calculation (Simplified Method)

Alternative Subcutaneous Management for Mild‑Moderate, Uncomplicated DKA

Insulin Infusion and Management of Diabetic Ketoacidosis

Insulin Selection and Standard Dosing

The American Diabetes Association (ADA) recommends using only regular (short‑acting) insulin for intravenous infusion; rapid‑acting analogs must not be administered intravenously. 17
For moderate‑to‑severe DKA, the ADA protocol calls for an initial IV bolus of regular insulin 0.1 U/kg given as a direct push, followed by a continuous infusion of 0.1 U/kg/h via an IV pump. 17
Insulin should be prepared by adding 100 U regular insulin to 100 mL normal saline, yielding a concentration of 1 U/mL. 17

Alternative Low‑Dose Protocol (Pediatrics or Mild DKA)

The Pediatric Society guideline (Pediatrics, 2008) suggests a low‑dose regimen without a bolus: start a continuous infusion of regular insulin at 0.05 U/kg/h; this may lower the risk of hypokalemia, particularly in malnourished children. 18

Fluid and Electrolyte Management

Begin isotonic saline at 15–20 mL/kg/h for the first hour, administered concurrently with the insulin infusion. 17
Once serum potassium is ≥3.3 mEq/L and urine output is adequate, add 20–30 mEq/L potassium to each liter of replacement fluid. 17
Maintain serum potassium between 4–5 mEq/L throughout DKA treatment. 17

Glucose Control and Dextrose Addition

When plasma glucose falls to 250 mg/dL, switch the IV fluid to D5W combined with 0.45–0.75 % NaCl while continuing the insulin infusion at the same rate. 17
Target a glucose range of 150–200 mg/dL until full resolution of ketoacidosis. 17
In euglycemic DKA (initial glucose < 250 mg/dL), start D5W together with normal saline from the outset of insulin therapy. 17

Monitoring Frequency

The ADA advises checking blood glucose, serum electrolytes (especially potassium), venous pH, serum bicarbonate, anion gap, BUN, creatinine, and osmolality every 2–4 hours until the patient is stable. 17

Transition to Subcutaneous Insulin

Administer a long‑acting basal insulin (glargine or detemir) subcutaneously 2–4 hours before stopping the IV insulin infusion. 17
Continue the IV insulin infusion for an additional 1–2 hours after the basal dose to ensure adequate absorption. 17
The basal dose should be approximately 50 % of the total 24‑hour IV insulin amount, given as a single daily injection; the remaining 50 % is divided equally among three meals as rapid‑acting prandial insulin. 17

Alternative Subcutaneous‑Only Approach for Mild‑Moderate DKA

For hemodynamically stable, alert patients with mild‑moderate DKA, the ADA notes that subcutaneous rapid‑acting insulin analogs (0.1–0.2 U/kg every 1–2 hours) combined with aggressive IV fluid replacement can be as effective and more cost‑effective than continuous IV insulin. 17

Safety Checks and Common Pitfalls (ADA Recommendations)

Potassium prerequisite: Do not initiate insulin if serum potassium is <3.3 mEq/L; replete potassium first. 17
Glucose‑driven insulin hold: Never hold insulin when glucose falls; instead add dextrose to the IV fluid while maintaining insulin infusion to clear ketones. 17
Overlap before discontinuation: Never stop IV insulin abruptly; overlap with subcutaneous basal insulin for 2–4 hours to prevent DKA recurrence. 17
Ketone monitoring: Do not rely solely on urine ketones; they lag behind serum ketone clearance and do not measure β‑hydroxybutyrate. 17
Underdosing in severe DKA: If acidosis persists despite adequate hydration, increase insulin to 4–6 U/h (or higher) while providing appropriate glucose supplementation. 17

Standardized Preparation and Administration of Intravenous Insulin in Critical Care

Preparation of the Insulin Infusion

Prepare a standardized insulin solution of 1 U/mL by adding 100 U of regular human insulin to 100 mL of 0.9 % sodium chloride; this concentration minimizes dosing errors and enables consistent titration in all critically ill patients【19】【20】【21】.
Prime the infusion tubing with 20 mL of the prepared solution (loss‑volume priming) before connecting to the patient to ensure the correct concentration reaches the bloodstream and to prevent insulin adsorption to the tubing walls【19】【20】.

Initial Dosing and Glycemic Targets

For general hyperglycemia in the ICU, start the insulin infusion at a rate of 0.5–1 U per hour and adjust based on glucose measurements taken every 1–2 hours【19】.
Aim for a target glucose range of 140–180 mg/dL (7.8–10.0 mmol/L) for the majority of critically ill patients【19】.

Monitoring of Glucose and Electrolytes

Measure serum potassium every 2–4 hours until the patient’s potassium stabilizes, because insulin drives potassium intracellularly and can precipitate hypokalemia【19】.
Maintain serum potassium in the 4–5 mEq/L range by adding 20–30 mEq of potassium per liter of IV fluid once renal function permits【19】.

Transition to Subcutaneous Basal Insulin

Administer a long‑acting basal insulin (e.g., glargine or detemir) 2–4 hours before stopping the IV insulin infusion to prevent rebound hyperglycemia or recurrence of diabetic ketoacidosis【19】【22】.
Use approximately 50 % of the total IV insulin dose delivered over the preceding 24 hours as the single daily dose of the long‑acting basal insulin【22】.
Divide the remaining 50 % of the 24‑hour IV insulin dose equally among the three daily meals as rapid‑acting insulin to cover prandial glucose excursions【22】.

Indications for IV versus Subcutaneous Insulin

IV insulin infusion is preferred for hemodynamically unstable patients requiring vasopressor support, for type 1 diabetic patients in the ICU, and whenever rapid, flexible titration is needed to achieve strict glycemic control【19】.
Subcutaneous insulin regimens become acceptable once the patient is hemodynamically stable, alert, and has resolved the acute critical illness, allowing a transition to basal‑bolus therapy【19】.

Safety Pitfalls to Avoid

Do not discontinue the IV insulin infusion without first overlapping with a basal subcutaneous insulin dose administered 2–4 hours earlier; failure to do so is the most common cause of recurrent diabetic ketoacidosis【19】.

Insulin Therapy in Hyperglycemic Emergencies Requires Prior Potassium Assessment

Physiologic Effects of Insulin on Potassium

Insulin actively drives potassium from the extracellular to the intracellular compartment, producing a rapid fall in serum potassium concentration. 23
In patients with severe hyperglycemia, initial serum potassium is often normal‑high or elevated despite a total body potassium deficit; the apparent hyperkalemia is generated by acidosis, dehydration, and lack of endogenous insulin rather than true potassium excess. 23

Potassium Thresholds Guiding Insulin Initiation (American Diabetes Association)

K⁺ < 3.3 mEq/L – Insulin must be withheld; potassium should be replaced first until the level reaches ≥3.3 mEq/L. This recommendation carries Class A evidence (well‑conducted randomized trials). 23
K⁺ 3.3–5.5 mEq/L – Insulin can be started safely. During therapy, add 20–30 mEq/L of potassium to the maintenance IV fluid once adequate renal function is confirmed. 23
K⁺ > 5.5 mEq/L – Initiate insulin immediately while delaying potassium supplementation; monitor the subsequent potassium decline and add replacement once the level falls below 5.5 mEq/L. 23

Monitoring and Target Potassium Levels

Serum potassium should be measured every 2–4 hours throughout insulin infusion to detect rapid shifts. 23
The therapeutic goal is to keep serum potassium between 4.0 and 5.0 mEq/L; a level of 3.5 mEq/L is considered the lower safety limit but not the optimal target. 23
Total body potassium depletion in diabetic ketoacidosis averages ≈ 1.0 mmol per kilogram of body weight, underscoring the need for aggressive replacement. 23

Predictable Potassium Shifts with Insulin

The magnitude of potassium decline after insulin correlates with the initial serum level: higher baseline potassium predicts a larger absolute drop (e.g., an initial K⁺ of 6.0 mEq/L may fall to ≤3.5 mEq/L after insulin administration). 23

Evidence Strength and Guideline Endorsement

The ADA’s directive to avoid insulin when K⁺ < 3.3 mEq/L is classified as Level A (high‑quality evidence from randomized controlled trials), making it one of the few Class A recommendations in the management of hyperglycemic crises. 23

Fluid and Electrolyte Management in Diabetic Ketoacidosis

Initial Assessment

Fluid Resuscitation Protocol

Insulin Therapy

Potassium Management (Class A Evidence)

Monitoring Specific to Children

Management of Euglycemic Diabetic Ketoacidosis with Gastrointestinal Symptoms

Pathophysiology

In patients presenting with mild diabetic ketoacidosis and concurrent gastrointestinal symptoms (nausea, vomiting, diarrhea), inadequate carbohydrate intake can precipitate starvation ketosis that combines with insulin deficiency, resulting in an euglycemic DKA presentation. 25

Fluid and Insulin Therapy (Modified for Euglycemia)

For euglycemic DKA (blood glucose ≈ 170 mg/dL), initiate dextrose‑containing intravenous fluids (e.g., D5W combined with 0.45–0.75 % NaCl) simultaneously with a continuous regular insulin infusion to prevent hypoglycemia while allowing insulin‑mediated ketone clearance. 25

Carbohydrate Replacement

Provide an estimated 150–200 g of carbohydrate per day to suppress ongoing ketogenesis in the setting of starvation ketosis. 25
If oral intake is tolerated, administer liquid carbohydrate sources (such as juice, broth, or sports drinks) in small, frequent portions to meet the daily carbohydrate target. 25

Supportive Care and Nutritional Re‑feeding

Administer anti‑emetic medication promptly to facilitate the early resumption of oral carbohydrate intake. 25
Once nausea resolves, aim for 45–50 g of carbohydrate every 3–4 hours, delivered as liquid or soft foods if solid meals are not yet tolerated. 25

Continuous Intravenous Insulin Infusion in Adult Critical Care

Standardized Preparation & Initiation

Prepare a standardized solution of 100 units regular human insulin in 100 mL 0.9 % sodium chloride (1 U/mL); this minimizes dosing errors and allows consistent titration across intensive care units. 26
Prime the infusion set with 20 mL of the prepared solution before patient connection to ensure accurate delivery and prevent insulin adsorption to tubing. 26
Initiate the infusion at 0.1 U/kg/h for diabetic ketoacidosis (DKA) or 0.5–1 U/h for non‑DKA hyperglycemia, aiming for a blood glucose target of 140–180 mg/dL in most critically ill patients. 26

Diabetic Ketoacidosis (DKA) – Initial Dosing

Give an IV bolus of 0.1 U/kg regular insulin followed immediately by a continuous infusion of 0.1 U/kg/h in adults with moderate‑to‑severe DKA. 27
In pediatric patients, omit the bolus and start a continuous infusion of 0.05–0.1 U/kg/h to reduce the risk of cerebral edema. 27

Safety Thresholds for Potassium

Do not start IV insulin if serum potassium is < 3.3 mEq/L; potassium must be repleted first (Class A evidence). 27
This potassium threshold is also listed as an absolute contraindication for IV insulin therapy. 27

Glucose Management During DKA

Aim for a glucose decline of 50–75 mg/dL per hour; if the decline is < 50 mg/dL in the first hour, verify adequate hydration and double the insulin infusion rate hourly until the desired decline is achieved. 27
When plasma glucose falls to 250 mg/dL, switch the IV fluid to 5 % dextrose with 0.45–0.75 % sodium chloride while maintaining the same insulin infusion rate to facilitate ketone clearance. 27

Potassium & Electrolyte Replacement in DKA

Add 20–30 mEq potassium per liter of IV fluid once serum potassium falls below 5.5 mEq/L and urine output is ≥ 0.5 mL/kg/h. 27
Use a mixture of ≈ 2/3 potassium chloride (or acetate) and 1/3 potassium phosphate to concurrently address phosphate depletion. 27
Maintain serum potassium 4.0–5.0 mEq/L throughout DKA treatment; monitor electrolytes every 2–4 hours. 27

General ICU Hyperglycemia Management

For non‑DKA hyperglycemia, start insulin at 0.5–1 U per hour and adjust based on glucose checks every 1–2 hours. 26
Target glucose 140–180 mg/dL for the majority of critically ill patients; a tighter range 110–140 mg/dL may be considered in selected cardiac surgery patients. 26

Monitoring Frequency

Check bedside blood glucose every 1–2 hours during the initial titration phase, then every 2–4 hours once the rate is stable. 26
In DKA, measure serum potassium, electrolytes, venous pH, bicarbonate, anion gap, BUN, creatinine, and osmolality every 2–4 hours until metabolic stability is achieved. 27

Transition to Subcutaneous Insulin

Administer a long‑acting basal insulin (e.g., glargine or detemir) 2–4 hours before stopping the IV infusion to ensure continuous insulin coverage and prevent rebound hyperglycemia or DKA recurrence. 27
Continue the IV insulin 1–2 hours after the subcutaneous basal dose to allow adequate absorption of the basal insulin. 27

Safety Considerations & Common Pitfalls

Never stop IV insulin abruptly without prior basal insulin overlap; abrupt cessation is the most common cause of recurrent DKA. 27
Never withhold insulin when glucose falls during DKA; instead, add dextrose to the IV fluid while maintaining the insulin infusion to continue ketone clearance. (Guideline principle – not a cited fact)

Indications for IV vs. Subcutaneous Insulin

IV insulin infusion is preferred for hemodynamically unstable patients requiring vasopressor support, type 1 diabetic patients in the ICU, and whenever rapid, flexible titration is needed for strict glycemic control. 26
Subcutaneous insulin regimens become acceptable once the patient is hemodynamically stable, alert, has resolved the acute critical illness, and can tolerate oral intake. 26

Insulin Drip Ordering in the ICU – Evidence‑Based Recommendations

Insulin Solution Preparation

Prepare a regular human insulin solution by adding 100 U of insulin to 100 mL of 0.9 % sodium chloride, yielding a final concentration of 1 U/mL. 28

Tubing Priming

Prior to patient connection, flush the infusion tubing with 20 mL of the prepared insulin solution to minimize drug adsorption and ensure accurate delivery. 28

Glycemic Targets for Non‑DKA Hyperglycemia

In ICU patients with severe hyperglycemia not meeting DKA criteria, aim for a serum glucose range of 140–180 mg/dL while on the insulin infusion. 28

Clinical Situations Favoring Intravenous Insulin Over Subcutaneous Administration

Hemodynamically unstable patients who require vasopressor support should receive IV insulin for rapid glucose control. 28
Patients with type 1 diabetes admitted to the ICU are recommended to be managed with IV insulin rather than subcutaneous regimens. 28
When rapid, flexible titration of insulin dose is needed (e.g., fluctuating glucose levels), IV insulin is preferred. 28
Presence of peripheral edema warrants IV insulin to avoid subcutaneous absorption variability. 28
Anticipated frequent interruptions of nutrition (e.g., intermittent feeding or procedures) favor IV insulin to maintain steady glucose management. 28

Potassium Management in Diabetic Ketoacidosis

Pre‑Insulin Potassium Threshold

The American Diabetes Association states that a serum potassium < 3.3 mEq/L is an absolute contraindication to initiating insulin therapy; this recommendation is supported by Class A evidence (high‑quality randomized trials). 29

Management Algorithms by Initial Potassium Level

Serum K⁺ < 3.3 mEq/L

Insulin must be withheld; isotonic saline is started at 15–20 mL/kg/h, urine output is confirmed ≥0.5 mL/kg/h, and potassium is aggressively replaced intravenously until the level reaches ≥3.3 mEq/L, after which insulin (0.1 U/kg IV bolus then 0.1 U/kg/h infusion) can be started. An electrocardiogram should be obtained before repletion. 29

Serum K⁺ 3.3–5.5 mEq/L

Insulin may be initiated safely. Once adequate urine output is confirmed, add 20–30 mEq of potassium to each liter of IV fluid; the potassium solution should consist of 2/3 potassium chloride (or potassium acetate) and 1/3 potassium phosphate. The target serum potassium throughout treatment is 4.0–5.0 mEq/L. [29][30]

Serum K⁺ > 5.5 mEq/L

Insulin is started immediately without delay, and no potassium is added to the initial IV fluids. Potassium is monitored every 2–4 hours because levels decline rapidly; supplementation (20–30 mEq/L) is begun once the level falls below 5.5 mEq/L. 29

Physiologic Rationale and Total‑Body Depletion

In DKA, total‑body potassium depletion averages about 1.0 mmol per kilogram of body weight, yet initial serum potassium is often normal or elevated due to extracellular shifts caused by acidosis, insulin deficiency, and hyperosmolality. 29
Potassium decline during treatment is driven by three mechanisms: (1) insulin‑mediated intracellular shift, (2) correction of acidosis reducing extracellular potassium, and (3) volume expansion diluting serum concentration. 29

Monitoring Protocols

Serum potassium should be measured every 2–4 hours throughout insulin infusion; the therapeutic goal is a serum potassium of 4.0–5.0 mEq/L, not merely >3.5 mEq/L. 29
In addition to potassium, glucose, venous pH, bicarbonate, anion gap, BUN, creatinine, and osmolality should be monitored at the same 2–4‑hour interval until the patient is metabolically stable. 29

Potassium Formulation Details

The recommended potassium supplementation of 20–30 mEq/L should be prepared with 2/3 potassium chloride (or potassium acetate) and 1/3 potassium phosphate. This composition simultaneously replenishes potassium and prevents severe hypophosphatemia (<1.0 mg/dL), which can lead to cardiac dysfunction, respiratory depression, and skeletal‑muscle weakness. 29

Common Pitfalls

Initiating insulin when serum potassium is < 3.3 mEq/L can precipitate fatal cardiac arrhythmias; this is the most critical error to avoid. 29
Discontinuing potassium supplementation prematurely—once the serum level normalizes—while total‑body potassium stores remain depleted, increases the risk of recurrent hypokalemia. 29

Guideline for Glycemic Management in Adult ICU Patients Using the Glucommander Algorithm

Glycemic Targets and Initiation Criteria

Initiate insulin infusion when blood glucose persistently exceeds 180 mg/dL and aim for a target range of 140–180 mg/dL to reduce hypoglycemia while maintaining effective control. 31
The Society of Critical Care Medicine advises against tighter targets of 80–139 mg/dL because they cause a four‑fold increase in severe hypoglycemia without improving mortality. Class A evidence. 31

Insulin Solution Preparation

Prepare the infusion solution by adding 100 U of regular human insulin to 100 mL of 0.9 % sodium chloride, yielding a concentration of 1 U/mL. 32

Potassium Safety Checks (Absolute Contra‑indication)

Do not start insulin if serum potassium is < 3.3 mEq/L; this is an absolute contraindication supported by Class A evidence. 32
Potassium management algorithm (all steps supported by the same source):
- K⁺ < 3.3 mEq/L – hold insulin, aggressively replete potassium until ≥ 3.3 mEq/L, then start insulin. 32
- K⁺ 3.3–5.5 mEq/L – insulin may be started; add 20–30 mEq/L potassium to IV fluids once adequate urine output is confirmed. 32
- K⁺ > 5.5 mEq/L – start insulin immediately; defer potassium supplementation until level falls below 5.5 mEq/L. 32
- Monitor potassium every 2–4 hours, aiming for a range of 4.0–5.0 mEq/L. 32

Fluid Resuscitation During Insulin Infusion

Begin the first hour with isotonic saline (0.9 % NaCl) at 15–20 mL/kg/hr. 32
Total fluid replacement should be roughly 1.5 × the 24‑hour maintenance requirement. 32
When plasma glucose falls to 250 mg/dL, switch to 5 % dextrose with 0.45–0.75 % NaCl while continuing the insulin infusion. 32
Add 20–30 mEq/L potassium to each liter of replacement fluid once potassium is < 5.5 mEq/L and renal function is adequate. Use a mixture of 2/3 potassium chloride (or acetate) and 1/3 potassium phosphate. 32

Glucose Monitoring Frequency

Check blood glucose every 1–2 hours during active insulin infusion, especially during the titration phase. 32
Protocols that use 4‑hourly glucose checks are linked to hypoglycemia rates > 10 % and should be avoided. 32

Hypoglycemia Prevention and Treatment

Treat hypoglycemia immediately without delay. 31
Administer 10 % dextrose in 50‑mL (5‑g) IV aliquots, repeating every minute until symptoms resolve. 32
Avoid 50 % dextrose because it can cause over‑correction and higher post‑treatment glucose levels. 32

Transition to Subcutaneous (Basal) Insulin

Give a long‑acting basal insulin (glargine or detemir) 2–4 hours before stopping the IV insulin infusion to prevent rebound hyperglycemia and DKA recurrence. 32
Continue the IV insulin infusion for 1–2 hours after the basal dose to ensure adequate absorption. 32

Indications for Continuous IV Insulin Over Subcutaneous Regimens

Continuous IV insulin infusion is the preferred method for acute management of critically ill adults. 31

Laboratory Monitoring Beyond Glucose (Every 2–4 Hours)

Serum electrolytes, especially potassium. 32
Blood urea nitrogen and creatinine. 32
Venous pH, serum bicarbonate, and anion gap. 32
Serum osmolality. 32

Critical Pitfalls to Avoid

Never start insulin when potassium is < 3.3 mEq/L; this can precipitate fatal cardiac arrhythmias. 32
Never discontinue IV insulin without a 2–4‑hour overlap of basal subcutaneous insulin, as this is a common cause of DKA recurrence. 32

Management of Hypoglycemia During Insulin Infusion in Diabetic Ketoacidosis

Immediate Management of Hypoglycemia

Administer 10–20 g of intravenous dextrose (e.g., 20–50 mL of 50 % dextrose or 100–200 mL of 10 % dextrose) titrated to raise the blood glucose above 70 mg/dL and avoid rebound hyperglycemia; re‑check glucose after 15 minutes and repeat dextrose as needed until the target is maintained. [American Society of Critical Care Medicine] 33

Transition to Dextrose‑Containing Maintenance Fluids

When plasma glucose declines to approximately 250 mg/dL, switch the IV fluid to 5 % dextrose in 0.45–0.75 % saline (D5W with half‑ or three‑quarter‑normal saline) while keeping the insulin infusion rate unchanged. [American Diabetes Association] 34

Monitoring Protocol During Insulin Infusion

Check capillary or venous blood glucose every 1–2 hours while the insulin infusion is active; after the glucose and infusion rate stabilize, extend monitoring to every 2–4 hours. [American Diabetes Association] 34
Measure serum electrolytes (especially potassium), venous pH, bicarbonate, and anion gap every 2–4 hours until metabolic stability is achieved. [American Diabetes Association] 34
Prior to each insulin dose adjustment, obtain a serum potassium level because insulin drives potassium intracellularly; severe hypokalemia (< 2.5 mEq/L) is linked to increased mortality. [Lancet Diabetes & Endocrinology] 35

Potassium Replacement During Hypoglycemia Correction

Maintain serum potassium in the 4.0–5.0 mEq/L range throughout DKA treatment by adding 20–30 mEq/L potassium to the IV fluids (using a mixture of potassium chloride/acetate and potassium phosphate). [Lancet Diabetes & Endocrinology] 35

Continuation of Insulin Infusion and Transition to Subcutaneous Basal Insulin

Do not discontinue or reduce the insulin infusion when blood glucose normalizes; continuous insulin is required for ketone clearance and to prevent rebound ketoacidosis. [American Diabetes Association] 34
Initiate subcutaneous basal insulin (e.g., glargine or detemir) 2–4 hours before stopping the IV insulin infusion to avoid rebound hyperglycemia and recurrent DKA. [American Diabetes Association] 34
Continue the IV insulin infusion for an additional 1–2 hours after the subcutaneous basal dose to ensure adequate absorption of the basal insulin. [American Diabetes Association] 34

Weight‑Based Intravenous Insulin Dosing and Transition in ICU Hyperglycemia

Initial Dosing and Glycemic Targets

Initiate a continuous intravenous regular insulin infusion at 0.1 units/kg/hour (or 0.5–1 U/h for non‑DKA hyperglycemia) in persistently hyperglycemic ICU patients, aiming for a glucose range of 140–180 mg/dL for most critically ill individuals; a tighter target of 110–140 mg/dL may be considered in selected cardiac surgery patients if it can be achieved without significant hypoglycemia. 36

Insulin Infusion Titration Protocol

Adjust the insulin infusion rate using validated written or computerized protocols that provide predefined adjustments based on recent glycemic trends and the current insulin infusion rate. 36

Transition to Subcutaneous Basal‑Bolus Therapy

Administer a long‑acting basal insulin (e.g., glargine or detemir) 2–4 hours before stopping the IV insulin infusion to maintain continuous insulin coverage and prevent rebound hyperglycemia or recurrence of DKA. 36
Continue the IV insulin infusion for an additional 1–2 hours after the subcutaneous basal dose to allow adequate absorption of the basal insulin. 36

Criteria and Monitoring for Resolution of Empagliflozin‑Induced Euglycemic DKA

Biochemical Resolution Criteria

The American Diabetes Association defines DKA resolution as requiring all of the following simultaneously: glucose < 200 mg/dL (11.1 mmol/L), bicarbonate ≥ 18 mmol/L, pH > 7.30, anion gap ≤ 12 mmol/L, and β‑hydroxybutyrate < 1.0 mmol/L. Meeting every criterion is required before transitioning to subcutaneous insulin. [37][38]
A bicarbonate level of 18 mmol/L is considered the lower threshold for DKA resolution. [37][38]
A venous pH > 7.30 indicates adequate acid‑base recovery. 38
Glucose < 200 mg/dL (11.1 mmol/L) is an accepted glucose target during DKA treatment. 38

Ketone Monitoring

Serum β‑hydroxybutyrate measurement is preferred over urine ketone testing because it reflects real‑time ketone clearance; urine ketones may lag and give a false impression of ongoing ketosis. [37][38]
Persistent elevation of β‑hydroxybutyrate ≥ 1.0 mmol/L signals that ketogenesis has not resolved and insulin infusion must be continued. [37][38]

Insulin Management

Continuous IV insulin infusion should be maintained until serum ketones fall below 1.0 mmol/L, regardless of normalized glucose, to suppress ongoing ketogenesis and prevent recurrent DKA. 38
Premature discontinuation of insulin is the most common cause of recurrent DKA. 38

Pitfalls in Ketone Assessment

Reliance on urine ketone strips alone is discouraged because they lag behind serum β‑hydroxybutyrate clearance and may mislead clinicians during treatment. [37][38]

Evidence‑Based Recommendations for Insulin Therapy in Diabetic Ketoacidosis

Initial Fluid Resuscitation

Begin isotonic saline (0.9 % NaCl) at 15–20 mL/kg per hour during the first hour to restore intravascular volume (approximately 1–1.5 L in an average adult) 39.
After the first hour, calculate corrected serum sodium by adding 1.6 mEq/L for each 100 mg/dL glucose above 100 mg/dL 39.
If the corrected sodium is normal or elevated, switch to 0.45 % NaCl at 4–14 mL/kg per hour 39.
If the corrected sodium is low, continue 0.9 % NaCl at 4–14 mL/kg per hour 39.

Potassium Management

Total body potassium depletion is universal (≈3–5 mEq/kg) even when initial serum potassium appears normal or high; therefore potassium should be routinely supplemented 39.
When serum potassium is 3.3–5.5 mEq/L, insulin may be started safely; add 20–30 mEq/L of potassium to the IV fluids (approximately 2/3 potassium chloride and 1/3 potassium phosphate) once adequate urine output is confirmed 39.

Insulin Dosing Adjustments

In children, omit the initial bolus and start a continuous infusion of 0.05–0.1 units/kg per hour to reduce the risk of cerebral edema 39.

Glucose Management During Insulin Infusion

When plasma glucose falls to 250 mg/dL, change IV fluids to 5 % dextrose with 0.45–0.75 % NaCl while maintaining the same insulin infusion rate 39.

Monitoring Protocol

Measure serum electrolytes (especially potassium), venous pH, bicarbonate, anion gap, BUN, creatinine, and osmolality every 2–4 hours until the patient is metabolically stable 39.

Bicarbonate Administration in Severe Acidosis

For patients with a pH < 6.9, consider administering 100 mmol sodium bicarbonate diluted in 400 mL sterile water, infused at 200 mL/hour 39.

Management of Underlying Causes and Infections

When infection is suspected, obtain bacterial cultures (urine, blood, throat) and initiate appropriate antibiotic therapy 39.

Guideline Recommendations for Intravenous Insulin Use in Liver Failure

1. Preferred Insulin Delivery Method

Continuous intravenous regular insulin infusion is the gold‑standard approach for critically ill patients with severe hyperglycemia, providing rapid and flexible titration that accommodates the unpredictable insulin sensitivity seen in liver failure due to reduced hepatic insulin clearance and altered glucose metabolism. 40

2. Glycemic Targets in Critical Illness

For most critically ill patients—including those with liver failure—the recommended glucose range is 140–180 mg/dL. Targeting a tighter range of 110–140 mg/dL raises the risk of hypoglycemia approximately four‑fold without delivering a mortality benefit, and therefore should be avoided. [41][40]

3. Insulin Therapy Strategy

Use of sliding‑scale insulin as the sole therapy is ineffective and is strongly discouraged; a structured insulin regimen (e.g., continuous IV infusion or basal‑bolus strategy) should be employed instead. [41][40]

Guidelines for Initiating Oral Intake in Clinically Stable Diabetic Ketoacidosis Without ABG Confirmation

Clinical Assessment

Oral intake may be started when the patient is clinically stable—alert, without Kussmaul respirations, and showing no signs of ongoing metabolic decompensation—even if arterial blood gas results are unavailable. 42
The absence of acidotic breathing strongly indicates that severe acidosis (pH < 7.0–7.1) is unlikely, supporting the decision to advance care based on clinical judgment. 43

Transition Protocol

Subcutaneous basal insulin (e.g., glargine or detemir) should be administered 2–4 hours before stopping the intravenous insulin infusion; the IV insulin is then discontinued at the moment oral feeding resumes to avoid rebound hyperglycemia and recurrent DKA. 42
A rapid‑acting insulin analog (lispro, aspart, or glulisine) should be given with the first meal, with the dose titrated to the carbohydrate content of that meal. 42

Insulin‑Resistance Considerations

If the IV insulin infusion rate is ≥ 5 IU/hour, this reflects marked insulin resistance; the infusion should not be stopped until the rate has fallen to ≤ 0.5 IU/hour. 42

Criteria for Feeding Without Formal ABG Confirmation

Formal ABG‑confirmed resolution of DKA (pH > 7.3, bicarbonate ≥ 18 mEq/L) is not required before initiating oral intake when the patient is clinically well; clinical stability alone permits feeding even if biochemical resolution is incomplete. 42

Guideline for Potassium and Fluid Management in Diabetic Ketoacidosis with Severe Hypokalemia and Hypernatremia

Initial Fluid Resuscitation

Begin isotonic saline (0.9 % NaCl) at 15–20 mL kg⁻¹ h⁻¹ (≈1–1.5 L in the first hour) while insulin is withheld, to restore intravascular volume, improve renal perfusion, and start correcting hypernatremia. 44
After the first‑hour bolus, if the corrected serum sodium remains elevated, switch to 0.45 % NaCl at 4–14 mL kg⁻¹ h⁻¹. 44
Limit the change in serum osmolality to ≤3 mOsm kg⁻¹ h⁻¹ to reduce the risk of cerebral edema. 44

Potassium Replacement – Pre‑Insulin

Once adequate urine output (≥0.5 mL kg⁻¹ h⁻¹) is confirmed, add 20–40 mEq K⁺ per liter of IV fluid. 44
Use a potassium mixture of 2/3 potassium chloride (or potassium acetate) and 1/3 potassium phosphate. 44
Maintain serum potassium ≥3.3 mEq L⁻¹ before any insulin is started; this threshold is an absolute contraindication with Class A evidence because values below this can precipitate fatal cardiac arrhythmias and respiratory muscle weakness. 44
The overall target potassium range during DKA treatment is 4.0–5.0 mEq L⁻¹. 44

Hypernatremia Assessment

Calculate corrected sodium by adding 1.6 mEq L⁻¹ for each 100 mg dL⁻¹ of glucose above 100 mg dL⁻¹. 44

Insulin Initiation

Initiate insulin only after serum potassium is ≥3.3 mEq L⁻¹. 44
Administer an IV bolus of 0.1 U kg⁻¹ regular insulin, followed by a continuous infusion of 0.1 U kg⁻¹ h⁻¹. 44

Ongoing Potassium Management After Insulin

While insulin is running and serum potassium is 3.3–5.5 mEq L⁻¹, continue adding 20–30 mEq K⁺ per liter of IV fluid. 44
Monitor serum potassium every 2–4 hours throughout active DKA therapy. 44
Recognize that insulin drives potassium intracellularly, causing a rapid decline in serum levels even though total body potassium depletion averages 3–5 mEq kg⁻¹. 44

Pathophysiology and Outcomes

Total body potassium depletion is universal in DKA, even when initial serum potassium appears normal or elevated. 44
Inadequate potassium monitoring and replacement is a leading cause of mortality in DKA. 44

Treatment Recommendations for Youth with Type 2 Diabetes Presenting with Ketoacidosis

Initial Insulin Therapy

In adolescents and young adults with type 2 diabetes who present with ketosis or diabetic ketoacidosis, initiate rapid‑acting subcutaneous insulin or continuous intravenous regular insulin promptly to correct hyperglycemia and metabolic derangement. 45

Transition to Oral Therapy

After resolution of acidosis, add metformin while maintaining subcutaneous insulin therapy to sustain glycemic control and prevent recurrence of ketoacidosis. 45

Guidelines for Intravenous Insulin Infusion in Critical Care

Indications and Contra‑indications

Intravenous regular insulin is indicated for critically ill patients who require vasopressor support, type 1 diabetics in the ICU, diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), or any situation that demands rapid, flexible titration of glucose‑lowering therapy【@1】【@2】.
Initiation of an insulin drip requires a serum potassium ≥ 3.3 mEq/L; values below this threshold are an absolute contraindication because they can precipitate fatal cardiac arrhythmias (Class A evidence)【@3】【@1】.

Preparation of Insulin Solution and Infusion Set‑up

Mix 100 U of regular human insulin with 100 mL of 0.9 % sodium chloride to obtain a 1 U/mL concentration; this standardized preparation reduces dosing errors and enables consistent titration across ICU settings【@2】【@1】.
Prior to patient connection, flush the IV tubing with 20 mL of the prepared insulin solution to prevent insulin adsorption to the tubing walls and to assure accurate delivery from the first moment【@2】【@1】.
Use a dedicated IV line for the insulin infusion whenever possible to avoid medication‑interaction problems【@4】.

Glucose and Electrolyte Management

Dextrose Supplementation

In DKA management, add dextrose‑containing fluids when plasma glucose falls to ≈250 mg/dL; this permits continued insulin infusion to clear ketones while preventing hypoglycaemia【@3】.
Typical dextrose provision is 100–150 g per day (e.g., D10W at 40 mL/h delivers ≈96 g/day)【@2】.

Potassium Replacement

Prepare potassium supplementation as a mixture of 2/3 potassium chloride (or acetate) and 1/3 potassium phosphate to address simultaneous potassium and phosphate depletion【@3】.
Add 20–30 mEq/L potassium to IV fluids once serum K⁺ is < 5.5 mEq/L and urine output is ≥ 0.5 mL/kg/h.【@3】
Maintain serum potassium between 4.0 – 5.0 mEq/L throughout the insulin infusion【@3】【@1】.
Monitor serum potassium every 2–4 hours during active insulin therapy, as insulin drives potassium intracellularly【@3】【@1】.

Insulin Dosing Protocols

Diabetic Ketoacidosis (Moderate–Severe)

Give an IV bolus of 0.1 U/kg regular insulin, followed by a continuous infusion of 0.1 U/kg/h (≈5–7 U/h in adults); this achieves a glucose decline of 50–75 mg/dL per hour【@3】.
In pediatric DKA, omit the initial bolus and start the infusion at 0.05–0.1 U/kg/h to reduce the risk of cerebral edema【@3】.

General ICU Hyperglycaemia (Non‑DKA)

Initiate insulin at 0.5–1 U/h and adjust based on bedside glucose checks every 1–2 hours; target glucose 140–180 mg/dL for most critically ill patients【@1】.
More stringent targets of 110–140 mg/dL may be considered in selected cardiac‑surgery patients if they can be achieved without significant hypoglycaemia【@1】【@5】.

Monitoring and Safety

Check bedside glucose every 1–2 hours during the initial titration phase, then every 2–4 hours once the glucose level is stable; frequent monitoring prevents hypoglycaemia, which is more common in protocols that use 4‑hourly checks【@1】.
When possible, obtain arterial or venous blood samples (from the side opposite the glucose infusion) rather than capillary samples for glucose measurement【@2】.
In DKA, measure venous pH, bicarbonate, and anion gap every 2–4 hours until metabolic stability is reached【@3】.
Keep 10 % dextrose solution in 50‑mL aliquots (5 g per aliquot) at the bedside; this concentration is preferred for treating hypoglycaemia during an insulin drip because 50 % dextrose can cause over‑correction【@1】.
Treat any glucose < 70 mg/dL immediately with 10 % dextrose, repeating the dose every minute until symptoms resolve【@1】.
Do not rely on urine ketone testing alone, as urine ketones lag behind serum β‑hydroxybutyrate clearance【@3】.

Transition to Subcutaneous Insulin

Administer a long‑acting basal insulin (glargine or detemir) 2–4 hours before stopping the IV infusion; this overlap prevents rebound hyperglycaemia and recurrent DKA【@3】【@1】.
Continue the IV insulin infusion for an additional 1–2 hours after the subcutaneous basal dose to ensure adequate absorption【@3】.
Calculate the total daily subcutaneous insulin dose as roughly 50 % of the total 24‑hour IV insulin amount for basal coverage, with the remaining 50 % divided among three meals as rapid‑acting insulin【@2】.
Never discontinue the IV insulin abruptly without prior basal insulin overlap; abrupt cessation is the most common cause of recurrent DKA【@1】.